EARNEST Partners
BVS icon

EARNEST Partners’s Bioventus BVS Stock Holding History

EARNEST Partners’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-617,919
Closed -$4.33M – 1176
2022
Q3 		$4.33M Sell
617,919
-1,490
-0.2% -$11.7K 0.03% 192
2022
Q2 		$4.22M Buy
+619,409
New +$6.32M 0.03% 192

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

EARNEST Partners's BVS Position: Q4 2022 in Review

EARNEST Partners sold out of Bioventus (BVS) in Q4 2022, closing a stake of 617,919 shares — an estimated $4.33M sold.

EARNEST Partners first reported a position in BVS in Q2 2022 and held it in 2 quarters. The position peaked at $4.33M in Q3 2022. 84 funds tracked by Wall St. Rank hold BVS as of Q4 2022.

  • EARNEST Partners reported no remaining Bioventus position as of Q4 2022 after selling out during the quarter.
  • EARNEST Partners sold 617,919 Bioventus shares in Q4 2022, an estimated $4.33M.
  • EARNEST Partners first reported a position in Bioventus in Q2 2022 and held it in 2 quarters.
  • EARNEST Partners's Bioventus position peaked at $4.33M in Q3 2022.
  • 84 funds tracked by Wall St. Rank held Bioventus as of Q4 2022.

Based on EARNEST Partners's 13F filing for Q4 2022, filed 14 Feb 2023.